Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company’s shareholders, providing an update on corporate developments and business strategy. As outlined in the letter, Ehave has established and is executing on key partnerships that allow the company to generate revenue while demonstrating its utility for mental health researchers, pharmaceutical companies and clinicians, setting Ehave on a strong growth trajectory. Interested parties can access the full letter on the Company’s website at: https://www.ehave.com/about/shareholder-letter.
“Ehave has made a great deal of strategic and tactical progress this year toward fulfilling our vision to transform mental healthcare, and are excited to provide this context for our announcements” stated Prateek Dwivedi, President and CEO of Ehave. “Since our last update, we’ve established and expanded the commitments to our mental health (Multi Health Systems) and therapeutic (MedReleaf TSX: LEAF) partners, and entered into new partnerships to expand our market verticals to include the pharmaceutical industry (Aequus TSX-V: AQS). Meanwhile, we are preparing for our next set of trials of our new video games for assessment & remediation of ADD/ADHD developed in collaboration with The Hospital for Sick Children in Toronto. Separately and together, these partnerships will demonstrate the versatility and depth of our platform, which will drive value going forward.”
Ehave (Ticker: EHVVF) is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. Ehave’s mental health informatics platform facilitates objective, data-driven decision making while keeping patients informed and engaged throughout their mental healthcare journey. Ehave offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf (TSE: LEAF).
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.